Particle Data Platform

Lessons From MDMA Rejection

12:3013:49 · 79s

Stone recaps the Biden-era MDMA bid—controversial data, misconduct allegations, and an FDA advisory rejection—and frames Trump’s move as a sharp contrast.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.